Member Spotlight / News / Press Releases - June 29, 2023

Six new members join the EUCOPE network in June 2023

The European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE) announced the joining of six (6) new members at its quarterly Members Meeting on June 21st, 2023 following Board approval. The new members joining EUCOPE network are Azafaros, Deciphera Pharmaceuticals, Dyne Therapeutics, HemaNext, MediWound and Rocket Pharmaceuticals.

During the announcement, EUCOPE’s Secretary General Alexander Natz said, “We’re excited to welcome these new members, just after the announcement of the EU Pharma Package proposal – which showcases the need for partnership and collaboration when navigating the complex EU biopharmaceutical environment. Our latest members demonstrate that smaller companies are still the key drivers of life science innovation within the EU and the world and we are proud to give them a bigger voice within the EU and its Member States.” 

Learn more about the new members below.


Azafaros is a Dutch-based clinical-stage biotech company working on building a pipeline of disease-modifying therapeutics for people living with severe rare genetic diseases. Their lead clinical-stage program is AZ-3102, an orally available, brain-penetrant small molecule to treat ultra-rare metabolic disorders.

Anke Arnold-Tugulu, Head of Regulatory Affairs said: “EUCOPE membership will help Azafaros stay on top of European developments, especially regarding the changing regulatory and access environment. EUCOPE offers a platform for discussion and networking, providing opportunities to connect and share experiences with like-minded professionals and biotech companies in the orphan disease space.”



Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. They are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.

“The strength and sustained momentum of our European market entry is a testament to the tremendous work by our International team as we work towards bringing new, innovative medicines to Europe,” said Margarida Duarte, Senior Vice President, Head of International at Deciphera. “As a biotech company recently established in Europe and consisted of a highly experienced team, this membership at EUCOPE will expand our network and reach, enhancing our contribution towards shaping the future of the European Healthcare state.”



Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.

Shekhar Natarajan, Vice President, EU and International Regulatory Affairs said: ” We joined EUCOPE for the opportunity to collaborate and comment on key regulatory guidelines, process documents and position papers that are out for industry comments to ensure Dyne has a voice on these important matters. The opportunity to collaborate and interact with other industry members and Health Authorities on key topics such as regulatory pathways, regulatory reliance, rare disease, and orphan drug are essential in order to make Dyne more visible amongst the European community.”




Hemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company’s research and development efforts center on the study of hypoxically stored RBCs. The company’s aim is to significantly improve the quality of stored RBCs.

On joining EUCOPE, Suzanna van Straaten, Sr. Dir. Commercial and Market Access EMEA said: “Introducing Hemanext as a new member of EUCOPE is an exciting development for our company, as we hope to contribute to the enhancement of the network of innovative companies dedicated to addressing patients’ needs in Europe through an unwavering commitment to advancements in medical technology.  As patients are the center of everything we do, we are always looking for ways to accelerate the process of bringing our innovative red blood cell (RBC) transfusion therapy to patients worldwide and we hope this membership will do just that.  With EUCOPE’s guidance in regulatory and government affairs, Hemanext will gain the necessary insights to successfully navigate the dynamic European environment.”


MediWound Ltd. (NASDAQ: MDWD) is a global biopharmaceutical company specializing in the development, production and commercialization of biologic enzymatic debridement solutions that improve patient outcomes and reduce hospitalization times. The company is setting a new standard in wound care, providing fast, effective and efficient treatment with minimized tissue damage and reduced scarring. A leader in next-generation enzymatic debridement technology for over20 years, MediWound’s products are approved and sold in more than 40 countries, via a direct sales force in addition to strategic partners and distributors across the U.S., Europe and Asia.

Alicia Torrenova, Vice President Operations Europe said:“EUCOPE is a pivotal ally to facilitate pan-European collaborations, discussions and networking. EUCOPE’s broad involvement scope spanning regulatory policy, market access & reimbursement regulations, industrial cooperation forums along with a solid network of national and EU KOLs, make them a natural partner for further expansion of MediWound’s innovation across Europe.” 

Rocket Pharma

Rocket Pharmaceuticals is a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of AAV and LV genetic therapies for rare disorders with high unmet need, including hematologic and cardiovascular diseases.

Oswald Bentinck, VP, Global Head – Value and Access stated: “Rocket Pharma is excited to announce our membership with EUCOPE as we advance towards commercialization of our gene therapies. As a U.S.-based biotech company, we understand the importance of navigating the European regulatory, legal, and access landscape to bring our gene therapies to patients. We look forward to accessing EUCOPE’s invaluable insights, contacts, and experience to help efficiently navigate the European market, ensuring that our innovative therapies are best positioned to reach patients with rare diseases who need them as quickly as possible.”



EUCOPE is happy to have these innovative smaller companies join the network and looks forward to greater collaboration during this important year and more to continue improving and saving the lives of European patients through innovative therapies and medical technology.


For more information about EUCOPE membership

Visit our Benefits of Membership Page, or schedule an introductory call with our Business Development Manager.